Hyloris Outlines Ambitious Growth Strategy During Full-Year Results
Belgian Value-Added Medicines Specialist Wraps Up A Successful Year In Business
Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.
You may also be interested in...
Hyloris will make payments of up to $6.7m to Vaneltix, alongside a $500,000 loan, to support their collaboration to develop and commercialize Alenura, a first-line drug treatment for acute pain caused by interstitial cystitis that combines lidocaine and heparin.
The US FDA has set a PDUFA date for Hyloris’ Maxigesic IV 505(b)(2) NDA that is earlier than expected, following two positive Phase III trials, spurring hopes that the product could also see earlier commercialization and registration than previously anticipated.
Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.